Abstract: A system and method for screening for coronary heart disease is provided. The method includes the steps of retrieving a test for assessing risk of coronary heart disease, the test including a plurality of data fields relating to coronary risk factors; accessing a database to populate the data fields with information of an individual patient; and calculating a risk assessment of the individual patient developing coronary heart disease. A system includes a first database including a plurality of structured computerized patient records; a second database including a knowledge base relating to coronary heart disease, the second database including at least one test for determining coronary heart disease risk; and a processor for retrieving the at least one test from the second database, populating the at least one test with patient information retrieved from the first database and calculating a risk assessment for at least one patient.

Abstract: A method for creating and searching medical ontologies includes providing a semi-structured information source comprising a plurality of articles linked to each other, each article having one or more sections and each article is associated with a concept, creating a directed unlabeled graph representative of the information source, providing a plurality of labels, labeling a subset of edges, and assigning each unlabeled edge an equal probability of being assigned one of the labels. For each node, the probability of each outgoing edge is updated by smoothing each probability by an overall probability distribution of labels over all outgoing edges of each node, and the probability of each incoming edge is updated the same way. A label with a maximum probability is assigned to an edge if said maximum probability is greater than a predetermined threshold to create a labeled graph.

Abstract: Radiolabeled cyclic polypeptides, pharmaceutical compositions comprising radiolabeled cyclic polypeptides, and methods of using the radiolabeled cyclic polypeptides. Such polypeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).

Abstract: Methods and apparatus for facilitating the synthesis of compounds in a batch device are presented. Application of the batch type microfluidic devices to the synthesis of radiolabeled compounds is described. These methods and apparatus enable the selective introduction of multiple reagents via an enhanced rotary flow distribution valve through a single inlet port of the synthetic device. The sequential introduction of multiple reagents through a single inlet port allows an optimal delivery of highly concentrated reagents into the reactor and facilitates the synthesis of the desired products with a minimal loss of materials during transfers, which is critical to the synthesis of radiolabeled biomarkers.

Abstract: A method for sequence tagging medical patient records includes providing a labeled corpus of sentences taken from a set of medical records, initializing generative parameters ? and discriminative parameters {tilde over (?)}, providing a functional LL?C×Penalty, where LL is a log-likelihood function LL = log ? ? p ? ( ? , ? ~ ) + ? l = 1 M ? ? [ log ? ? p ? ( X l , Y l | ? ~ ) - log ? ? p ? ( X l | ? ~ ) ] + ? l = 1 M ? ? log ? ? p ? ( X l | ? ) , ? Penalty = ? y ? V Y ? ( em y 2 + tr y 2 + e ? ? m ~ y 2 + t ? ? r ~ y 2 ) , where emy=1???xi?VXp(xi|y), e{tilde over (m)}y=1???xi?VX{tilde over (p)}(xi|y) are emission probability constraints, try=1???yi?VYp(yi|y), t{tilde over (r)}y=1???yi?VY{tilde over (p)}(yi|y) are transition probability constraints, and extracting gradients of LL?C×Penalty with respect to the transition and emission probabilities and solving ?k*,{tilde o

Abstract: Described herein are automated, integrated microfluidic device comprising a chemical reaction chip comprising for performing chemical reaction, a microscale column integrated with the chip and configured for liquid flow from the column to at least one flow channel, and wherein the fluid flow into the column is controlled by on-chip valves; and comprising at least two on-chip valves for controlling fluid flow in the microfluidic device.

Abstract: Knowledge-based interpretable predictive modeling is provided. Expert knowledge is used to seed training of a model by a machine. The expert knowledge may be incorporated as diagram information, which relates known causal relationships between predictive variables. A predictive model is trained. In one embodiment, the model operates even with a missing value for one or more variables by using the relationship between variables. For application, the model outputs a prediction, such as the likelihood of survival for two years of a lung cancer patient. A graphical representation of the model is also output. The graphical representation shows the variables and relationships between variables used to determine the prediction. The graphical representation is interpretable by a physician or other to assist in understanding.

Abstract: Methods and devices for a fully automated synthesis of radioactive compounds for imaging, such as by positron emission tomography (PET), in a fast, efficient and compact manner are disclosed. In particular, the various embodiments of the present invention provide an automated, stand-alone, hands-free operation of the entire radiosynthesis cycle on a microfluidic device with unrestricted gas flow through the reactor, starting with target water and yielding purified PET radiotracer within a period of time shorter than conventional chemistry systems. Accordingly, one aspect of the present invention is related to a microfluidic chip for radiosynthesis of a radiolabeled compound, comprising a reaction chamber, one or more flow channels connected to the reaction chamber, one or more vents connected to said reaction chamber, and one or more integrated valves to effect flow control in and out of said reaction chamber.

Abstract: The present application is directed to radiolabeled cyclic polyazapeptides, pharmaceutical compositions comprising radiolabeled cyclic polyazapeptides, and methods of using the radiolabeled cyclic polyazapeptides. Such polyazapeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).

Abstract: Modeling of prognosis of survivability, side-effect, or both is provided. For example, RILI is predicted using bullae information. The amount, volume or ratio of Bullae, even alone, may indicate the likelihood of complication, such as the likelihood of significant (e.g., stage 3) pneumonitis. As another example, RILI is predicted using uptake values of an imaging agent. Standardized uptake from a functional image (e.g., FDG uptake from a positron emission image), alone or in combination with other features, may indicate the likelihood of side-effect. In another example, survivability, such as two-year survivability, is predicted using blood biomarkers. The characteristics of a patient's blood may be measured and, alone or in combination with other features, may indicate the likelihood of survival. The modeling may be for survivability, side-effect, or both and may use one or more of the blood biomarker, uptake value, and bullae features.

Abstract: A method, including receiving multi-labeler data that includes data points labeled by a plurality of labelers; building a model from the multi-labeler data, wherein the model includes an input variable that corresponds to the data points, a label variable that corresponds to true labels for the data points, and variables for the labels given by the labelers; and executing the model, in response to receiving new data points, to determine a level of expertise of the labelers for the new data points.

Abstract: A method for predicting survival rates of medical patients includes providing a set D of survival data for a plurality of medical patients, providing a regression model having an associated parameter vector ?, providing an example x0 of a medical patient whose survival probability is to be classified, calculating a parameter vector {circumflex over (?)} that maximizes a log-likelihood function of ? over the set of survival data, l(?|D), wherein the log likelihood l(?|D) is a strictly concave function of ? and is a function of the scalar x?, calculating a weight w0 for example x0, calculating an updated parameter vector ?* that maximizes a function l(?|D?{(y0,x0,w0)}), wherein data points (y0,x0,w0) augment set D, calculating a fair log likelihood ratio ?f from {circumflex over (?)} and ?* using ?f=?(?*|x0)+sign(?({circumflex over (?)}|x0)){l({circumflex over (?)}|D)?l(?*|D)}, and mapping the fair log likelihood ratio ?f to a fair price y0f, wherein said fair price is a probability that class label y0 for exam

Abstract: The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.

Abstract: The present invention provides methods and compositions for predicting patient responses to cancer treatment using hypoxia gene signatures. These methods can comprise measuring in a biological sample from a patient the levels of gene expression of a group of the genes designated herein. The present invention also provides for microarrays that can detect expression from a group of genes.

Abstract: Disclosed herein are novel radiolabeled nucleosides and methods for detecting cellular proliferation in a mammal, the method comprising administrating an effective amount of a radiolabeled nucleoside; the method comprising: a) administering to the mammal a diagnostically effective amount of the nucleoside to the mammal; b) allowing the nucleoside to distribute into the effective tissue; and c) imaging the tissue, wherein an increase in binding of the compound to tissue compared to a normal control level of binding indicates that the mammal is suffering from a disease involving cellular proliferation.

Abstract: A technique is provided for automatically generating performance measurement information. At least some of the obtained performance measurement information may be derived from unstructured data sources, such as free text physician notes, medical images, and waveforms. The performance measurement may be sent to a health care accreditation organization. The health care accreditation organization can use the performance measurement to evaluate a health care provider for its quality of patient care. Alternatively, performance measurement information can be provided directly to consumers.

Abstract: A method and system correlate candidate information and provide batch classification of a number of related candidates. The batch of candidates may be identified from a single data set. There may be internal correlations and/or differences among the candidates. The candidates may be classified taking into consideration the internal correlations and/or differences. The locations and descriptive features of a batch of candidates may be determined. In turn, the locations and/or descriptive features determined may used to enhance the accuracy of the classification of some or all of the candidates within the batch. In one embodiment, the single data set analyzed is associated with an internal image of patient and the distance between candidates is accounted for. Two different algorithms may each simultaneously classify all of the samples within a batch, one being based upon probabilistic analysis and the other upon a mathematical programming approach. Alternate algorithms may be used.

Abstract: A system and method for diagnosis and treatment decisions based on information maximization is disclosed. Utilizing patient information as well as clinical records from other patients can reduce the uncertainty in both diagnosis and treatment options. The information maximization may consider additional data such as risk, cost, and comfort in making a proper medical decision.

Abstract: Automated treatment planning is provided with individual specific consideration. One or more prognosis models indicate survivability as a function of patient specific information for a given dose. By determining survivability for a plurality of doses, the biological model represented by survivability as a function of dose is determined from the specific patient. Similarly, the chances of complications or side effects are determined. The chance of survivability and chance of complication are used as or instead of the tumor control probability and normal tissue complications probability, respectively. The desired tumor dosage and tolerance dosage are selected as a function of the patient specific dose distributions. The selected dosages are input to an inverse treatment planning system for establishing radiation treatment parameters.

Abstract: The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.